Rapport Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Rapport Therapeutics, Inc. (RAPP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 67.4% of the shares are freely tradable; institutional investors hold 109.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.95 | 7,172,894 | +0.1 | 06/30/2026 |
| TRV GP V, LLC | 13.09 | 6,280,525 | -12.0 | 06/30/2026 |
| ARCH VENTURE CORP | 7.77 | 3,728,738 | +0.0 | 06/30/2026 |
| Capital Research & Mgmt Co - Division 3 | 6.09 | 2,921,958 | -5.7 | 06/30/2026 |
| The Goldman Sachs Group Inc | 6.07 | 2,910,449 | -1.1 | 06/30/2026 |
| BlackRock Inc | 5.63 | 2,699,786 | +7.7 | 06/30/2026 |
| Cormorant Asset Management, LLC | 5.54 | 2,657,521 | -10.1 | 06/30/2026 |
| Sofinnova Ventures | 3.97 | 1,904,408 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 6.51 | 3,121,012 | -7.7 | 09/30/2026 |
| Fidelity Growth Company Fund | 4.70 | 2,257,056 | +0.3 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Healy James | Director | 2,873,888 | 72,996,755 $ | Oct 28, 2026 | indirect |
| Ceesay Abraham | Chief Executive Officer | 450,035 | 11,430,889 $ | Oct 21, 2026 | direct |
| Yeleswaram Krishnaswamy | Chief Development Officer | 195,862 | 4,974,895 $ | Aug 25, 2026 | direct |
| Gault Cheryl | Chief Operating Officer | 139,914 | 3,553,816 $ | Sep 30, 2026 | direct |
| Paul Steven M | Director | 77,380 | 1,965,452 $ | Oct 22, 2026 | indirect |
| Ignelzi Troy A. | Chief Financial Officer | 15,500 | 393,700 $ | Oct 21, 2026 | direct |
| Young Wendy B. | Director | 13,289 | 337,541 $ | Oct 22, 2026 | direct |
| Maraganore John | Director | 9,411 | 239,039 $ | Oct 22, 2026 | indirect |
| Silva Paul M | Director | 3,680 | 93,472 $ | Oct 22, 2026 | indirect |
| Sanchez Ramiro | Director | 3,600 | 91,440 $ | Oct 23, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Healy James | Director | Buy | 6,933 | 21.00 | 145,593 |
| Oct 28, 2026 | Healy James | Director | Buy | 3,772 | 21.00 | 79,212 |
| Oct 28, 2026 | Healy James | Director | Buy | 6,395 | 21.00 | 134,295 |
| Oct 28, 2026 | Healy James | Director | Buy | 952,380 | 21.00 | 19,999,980 |
| Oct 23, 2026 | Sanchez Ramiro | Director | Buy | 3,600 | 27.35 | 98,478 |
| Oct 22, 2026 | Silva Paul M | Director | Buy | 3,680 | 27.08 | 99,636 |
| Oct 22, 2026 | Young Wendy B. | Director | Buy | 3,789 | 26.39 | 99,992 |
| Oct 22, 2026 | Paul Steven M | Director | Buy | 35,714 | 27.28 | 974,278 |
| Oct 22, 2026 | Maraganore John | Director | Buy | 1,172 | 26.92 | 31,547 |
| Oct 22, 2026 | Maraganore John | Director | Buy | 8,239 | 26.38 | 217,344 |
| Oct 21, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 2,210 | 29.16 | 64,448 |
| Oct 21, 2026 | Ignelzi Troy A. | Chief Financial Officer | Buy | 5,500 | 26.10 | 143,550 |
| Oct 7, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 1,147 | 30.66 | 35,167 |
| Oct 6, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 3,375 | 32.03 | 108,106 |
| Sep 30, 2026 | Gault Cheryl | Chief Operating Officer | Sell | 2,075 | 33.76 | 70,043 |
| Sep 30, 2026 | Gault Cheryl | Chief Operating Officer | Sell | 7,925 | 33.04 | 261,813 |
| Sep 23, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 43 | 41.05 | 1,765 |
| Sep 23, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 215 | 39.86 | 8,570 |
| Sep 23, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 1,952 | 39.05 | 76,230 |
| Sep 8, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 1,069 | 46.01 | 49,190 |
| Sep 8, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 7,141 | 45.56 | 325,308 |
| Aug 25, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 18,921 | 49.57 | 937,957 |
| Aug 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 16,201 | 51.06 | 827,184 |
| Aug 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 20,799 | 50.31 | 1,046,421 |
| Aug 24, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 13,160 | 50.00 | 657,978 |
| Aug 19, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 404 | 49.90 | 20,160 |
| Aug 11, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 5,794 | 48.62 | 281,721 |
| Aug 11, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 19,500 | 48.04 | 936,846 |
| Aug 11, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 3,664 | 46.90 | 171,837 |
| Aug 10, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 8,370 | 46.75 | 391,280 |
| Aug 10, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 14,171 | 45.97 | 651,492 |
| Jul 27, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 7 | 42.74 | 299 |
| Jul 27, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 2,203 | 42.11 | 92,762 |
| Jul 14, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 2,729 | 40.57 | 110,722 |
| Jul 14, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 5,481 | 39.72 | 217,715 |
| Apr 17, 2026 | Krishnaswamy Yeleswaram | Insider | Sell | 20,225 | 39.99 | 808,798 |
| Apr 17, 2026 | Rock Ventures V L.P. Third | Major Shareholder | Sell | 426,005 | 40.32 | 17,176,522 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.